Shaun Ilan

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

Genome Compiler Israel Ltd. develops software for personalized synthetic genome design. It provides an intuitive all-in-one software platform for genetic engineers, molecular and synthetic biologists. The company was founded by Omri Amirav-Drory Nir Ben Moshe, Yogev Debbi and Roy Nevo in 2011 and is headquartered in Tel Aviv, Israel.

NFX Capital Management LLC (NFX Capital) is a venture capital firm founded in 2015. The firm is headquartered in San Francisco, California.

Metabiotech Corp. operates a platform technology for reading and fixing DNA. Its synthetic biology solutions accelerate the design-build-test cycle for biotechnology and bioengineering and genomics pipeline that discovers clinically actionable genetic information for human diseases. The company was founded by Tuval Ben-Yehezkel and is headquartered in San Jose, CA.

Mammoth Biosciences, Inc. operates CRISPR-based platform for disease detection. The firm offers its services under the categories of bioinformatics, biotechnology, genetics, health diagnostics and life science. The company was founded by Ashley Tehranchi, Janice Chen, Jennifer A. Doudna, Lucas Harrington and Trevor Martin and is headquartered in South San Francisco, CA.

Omri AD Tech.Bio Ltd. was founded by Omri Amirav-Drory on September 17, 2019 and is headquartered in Herzliya, Israel.

Immunai, Inc. engages in decoding of immune system to improve health. It offers an immune profiling platform, which is used to advance research and development in checkpoint blockade, cancer cell therapy, and cancer vaccines. The company was founded by Noam Solomon, Luis Voloch, Danny Wells, Ansuman Satpathy and Dan R. Littman in December 2018 and is headquartered in New York, NY.

C2i Genomics, Inc. is engaged in the research and development on cancer. It provides ultrasensitive test for cancer. The company was founded by Asaf Zviran and Ezra Sofer in 2019 and is headquartered in New York, NY.

Light Bio, Inc. engages in other technology industry. The company is headquartered in Mount Horeb, WI.

Wild Biotech Ltd. develops a drug discovery platform. The private company is based in Rehovot, Israel. The Israeli company was founded by Ido Bachelet, Neta Raab, and Doron Levin. The CEO is Neta Raab.

Pangea Therapeutics Ltd. is an Israeli company that specializes in developing a proprietary tumor intelligence platform called Technology Enlight. The company is based in Tel Aviv, Israel. This platform enables a deeper understanding of how a tumor would respond to therapy by considering expression abnormalities, which are more common than actionable mutations. By combining these with tumor vulnerability maps, the platform uncovers many more clinically relevant insights than approaches based solely on genomic alterations. The company was founded by Eytan Ruppin, Eyal Gottlieb, Ze'ev Ronai. The CEO is Tuvik Beker.

Talus Bioscience, Inc. is a company that aims to address the primary cause of cancer and other diseases, which is regulome dysfunction. The company is based in Seattle, WA, and recently raised 9.75 million in seed funding to support their efforts. The company is focused on developing a drug discovery platform that can rapidly measure and manipulate the regulome, providing a new approach to cancer therapeutics. The company has also hired a new COO, Michelle Briscoe. Talus Bioscience was founded by Alex Federation and Lindsay Pino, with Alex Federation serving as CEO since incorporation.

Pepper Bio, Inc. develops an AI-based drug discovery platform. The American company was founded by Samantha Dale Strasser and Yu Jon Hu, with Yu Jon Hu serving as the CEO since incorporation.

Gilboa Therapeutics Ltd. is a preclinical-stage biopharmaceutical company located in Israel. The Israeli company is focused on developing novel and high-impact, next-generation cancer immunotherapies that harness the power of a patient's own immune system to treat cancer, improve outcomes, and save lives. Gilboa's proprietary technology, solidt, is an engineered cell therapy that targets multiple different tumor types and is intended to be used in combination with a wide range of antigen-specific antibodies. The company is driven by a sense of urgency to discover, develop, and rapidly bring their game-changing new therapeutics to cancer patients in need, significantly improving outcomes and saving lives.

Nanocarry Therapeutics Ltd. is a company based in Nes-Ziona, Israel. Nanocarry is developing a new class of therapeutics using bioengineered nanoparticles to treat oncology indications and brain diseases. The Israeli company's proprietary "plug and play" approach allows for easy modification to deliver a wide array of biologics safely and effectively to the brain and beyond. Nanocarry's first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer. The company aims to extend the reach of biological therapeutics to the brain to tackle CNS diseases head-on, pioneering a multidisciplinary approach that overcomes the blood-brain barrier. The company was founded by Rachela Popovtzer, Oshra Betzer, and Revital Mandil-Levin, with Revital Mandil-Levin serving as the CEO since incorporation.

La Jolla Labs, Inc. is a company that utilizes RNA biology, automation, cloud computing, and machine learning to provide innovative medical solutions to patients. The company is based in La Jolla, CA. The company specializes in various RNA-targeting modalities, such as splicing gapmers, miRNA, antisense oligonucleotides, and siRNA. The CEO of the company is Donald Jeff Milton.

Mana.Bio operates as an AI based drug delivery company. The company was founded by Yogev Debbi and Roy Nevo and is headquartered in United States.

ResistanceBio, Inc. is a company that focuses on overcoming treatment-resistant cancer. The company is based in San Carlos, CA. The company's mission is to defeat this type of cancer by developing a novel class of multi-targeted oncology treatments called Resistance Suppressing Therapy (REST). ResistanceBio was founded by Nicholas Goldner and Christopher Bulow, with Nicholas Goldner serving as the CEO since incorporation.